Page 2 - காடிலா சுகாதாரம் பகிர் ப்ரைஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from காடிலா சுகாதாரம் பகிர் ப்ரைஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In காடிலா சுகாதாரம் பகிர் ப்ரைஸ் Today - Breaking & Trending Today

Crisis over shortage of Remdesivir, Fabiflu to end by next fortnight

Crisis over shortage of Remdesivir, Fabiflu to end by next fortnight
SECTIONS
Last Updated: May 01, 2021, 12:32 PM IST
Share
Synopsis
An unprecedented surge in demand of some crucial medicines, used in treating Covid patients, has created a mess. Now companies like Cipla or Cadila, and others have increased production of vials manifolds. We promise supplies will be sufficient, Rajiv Singhal, General Secretary of All India Organisation of Chemists and Druggists(AIOCD), representing over 9.50 lakh chemists across the country, told IANS.
PTI
Though dire shortages of Covid-19 related medicines, seeing price spikes on the black market, the country s apex chemist body have assured that a sizable increase in supply of important life saving drugs from manufacturing companies would end the crisis by next fortnight in India. ....

Rajiv Singhal , India Organisation Of Chemists , General Secretary , All India Organisation , Co Vid , ராஜீவ் சிங்கால் , இந்தியா ஆர்கநைஸேஶந் ஆஃப் வேதியியலாளர்கள் , ஜநரல் செயலாளர் , அனைத்தும் இந்தியா ஆர்கநைஸேஶந் , இணை வித் ,

stocks to buy today: Don't be too bullish; wait for deeper corrections: Sandip Sabharwal

The market seems a little caught up in macro concerns Covid resurgence and earnings. Your view?
I don’t think Covid concerns are bothering the market as otherwise, it wouldn’t have rallied for the last three-four days. Last quarter’s results are going to be very good except for some auto stocks which got hit due to rising input prices and also may be some other consumer durables companies.
Most managements believe that post lockdown, the bounce-back would be similar to what happened the last time. But it looks like a tough act to follow. Last year, there was no inflation; this year inflationary pressures are very high. Last year, fear was more and the actual number of people who got infected was very less. This time, it is across the board, Extended families, people we know seem to have got this infection this time. So, the post Covid bounceback is not going to be as rapid. That will be a challenge for investors. ....

Sandip Sabharwal , Stocks To Buy Today , Asksandipsabharwal Com , Us Fed , Et Now , Stock Market , What To Buy , சண்டீப் சபர்வால் , ஸ்டாக்ஸ் க்கு வாங்க இன்று , எங்களுக்கு ஊட்டி , மற்றும் பலர் இப்போது , ஸ்டாக் சந்தை , என்ன க்கு வாங்க ,

reliance industries: Cadila best bet in midcap pharma space; expect decent result from Reliance: Sandip Sabharwal

Explore Now
My guess is that technology stocks could outperform in the near term. The only hitch is in good years their growth is expected to be 10-12% and margins could be under pressure, says
asksandipsabharwal.com.
It seems to be all about IT this morning whether it be earnings, whether it be deal buzz with Blackstone making that open offer to buy a stake in Mphasis. We are still watching out for strong deal wins from HCL Tech, Tech Mahindra. What do you find interesting this morning?
IT space is in a good zone right now because of the fact that growth outlook is decent and given the overall scenario in the markets where at least on the domestic economy front, a number of sectors on the discretionary consumption side could take a hit. ....

Sandip Sabharwal , Natco Pharma , Reliance Industries , Reliance Cadila , Asksandipsabharwal Com , Jio Platforms , Et Now , Stock Market , சண்டீப் சபர்வால் , நாட்கோ பார்மா , நம்பகத்தன்மை தொழில்கள் , ஜிோ தளங்கள் , மற்றும் பலர் இப்போது , ஸ்டாக் சந்தை ,

Zydus Cadila's Virafin granted restricted emergency use approval for treating Covid patients: DBT | India News

NEW DELHI: Drug Controller General Of India (DCGI) has granted restricted emergency use approval to Zydus Cadila s Virafin for treating patients showing moderate Covid-19 symptoms, the department of biotechnology said on Saturday.
Virafin is a pegylated interferon alpha-2b(PegIFN), which when subcutaneously injected to the patient in the early stages of infection, results in their faster recovery, it said.
The studies confirmed the safety, tolerability and efficacy of Virafin. The studies also reported that Viarfin reduces viral load and aid in managing the disease in a better way, such as reduction in the need for supplemental oxygen, thereby reducing the respiratory tension caused due to low oxygen levels, the DBT said. ....

Zydus Cadila , Zydus Cadila Virafin , Renu Swarup , Biotechnology Industry Research Assistance Council , Drug Controller General Of India , Pegylated Interferon , Ndia News , Ndia News Today , Oday News , Google News , Reaking News , ஜய்துச் காடிலா , ரேணு சுவருப் , உயிரி தொழில்நுட்பவியல் தொழில் ஆராய்ச்சி உதவி சபை , மருந்து கட்டுப்படுத்தி ஜநரல் ஆஃப் இந்தியா ,

Movers and Shakers: Stocks that will see action this week - The Hindu BusinessLine

Movers and Shakers: Stocks that will see action this week
|
Updated on
Hits new all-time high
The stock of Cadila Healthcare, which had been moving down gradually since the beginning of the year, found support at ₹420 by the end of March. The 200-day moving average coincided at ₹420 then and thus the bulls capitalised on the support to turn the tide in their favour. That is, since taking support at this level, the scrip has been appreciating with considerably good momentum. As a result, the stock rallied past the previous high of ₹509.2 and extended the gain. The price action looks bullish now and it is supported by indicators like the relative strength index and the moving average convergence divergence on the daily chart as they remain in their bullish territories. Also, the rally is accompanied by large volume. Hence, traders can buy the stock with a stop-loss at ₹540 for a target of ₹620. ....

Cadila Healthcare , Avenue Supermarts , Avenue Supermart , L Amp T , காடிலா சுகாதாரம் , அவென்யூ சூப்பர்மார்ட் , ல் ஆம்ப் டி ,